|
AU2016203848A1
|
|
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
|
|
AU2016203583A1
|
|
MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
|
|
AU2016202133A1
|
|
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
|
|
AU2014271293A1
|
|
MiRNA expression in human peripheral blood microvesicles and uses thereof
|
|
AU2014203454A1
|
|
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
|
|
AU2014203456A1
|
|
Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
|
|
AU2014202073A1
|
|
MicroRNA signatures in human ovarian cancer
|
|
AU2013267038A1
|
|
Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
|
|
AU2013245505A1
|
|
MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
|
|
AU2013224690A1
|
|
Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
|
|
AU2013206405A1
|
|
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
|
|
US2014369383A1
|
|
Thermal simulator
|
|
US2013316447A1
|
|
Oncolytic virus
|
|
AU2013204991A1
|
|
Viral gene products and methods for vaccination to prevent viral associated diseases
|
|
US2015051255A1
|
|
Glucose transporter inhibitors
|
|
US2014017272A1
|
|
Transgenic algae for delivering antigens to an animal
|
|
AU2012238336A1
|
|
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
|
|
WO2013106100A1
|
|
Methods for producing nanoparticles and using same
|
|
WO2013016658A1
|
|
Silvestrol, silvestrol analogs and uses thereof
|
|
WO2012158812A1
|
|
Devices and methods for measuring oxygen
|
